AMYT Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 apr 2024 @ 22:00):

Stats
Dagens volum	2.38M
Gjennomsnittsvolum	0.00
Markedsverdi	942.77M
EPS	$0 ( 2023-05-03 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	39.73
ATR14	$0.0580 (0.39%)

Volum Korrelasjon

Lang: 0.18 (neutral)

Kort: 0.00 (neutral)

Signal:(69.184) Neutral

Amryt Pharma plc Korrelasjon

10 Mest positive korrelasjoner
SUMO	0.97
DSPG	0.964
IDCC	0.946
NTUS	0.945
FSTR	0.945
STAY	0.941
HCCI	0.938
SENEA	0.935
SOHOB	0.935
ACLS	0.934

10 Mest negative korrelasjoner
DSGN	-0.991
CSSE	-0.989
YTEN	-0.98
FWRD	-0.978
CASA	-0.974
THTX	-0.974
ESPR	-0.97
PFSW	-0.97
GRTX	-0.968
BBLG	-0.963

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Amryt Pharma plc Korrelasjon - Valuta/Råvare

0.61
( weak )

0.50
( neutral )

-0.77
( moderate negative )

0.68
( moderate )

0.30
( neutral )

-0.36
( neutral )

Amryt Pharma plc Økonomi

Annual	2021
Omsetning:	$222.54M
Bruttogevinst:	$116.42M (52.32 %)
EPS:	$-0.573

FY	2021
Omsetning:	$222.54M
Bruttogevinst:	$116.42M (52.32 %)
EPS:	$-0.573

FY	2020
Omsetning:	$182.61M
Bruttogevinst:	$63.58M (34.82 %)
EPS:	$-3.30

FY	2019
Omsetning:	$58.12M
Bruttogevinst:	$16.12M (27.74 %)
EPS:	$-4.30

Financial Reports:

No articles found.

Amryt Pharma plc

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.